EUCTR2009-010068-41-GB进行中（未招募）不适用
Comparison of single and combination diuretics in low-renin hypertension - Pathway 3
Cambridge University Hospitals NHS Foundation Trust and University of0 个研究点目标入组 486 人开始时间: 2009年4月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 486
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Each of the following conditions must be satisfied. Patients can proceed to placebo run-in if biochemical data is available from previous 6 months, but cannot proceed to randomised treatment if eligibility not confirmed by baseline sample:
- •1. Age 18-79
- •2. Diagnosis of hypertension according to BHS criteria
- •3. Clinic seated SBP (mean of 2nd & 3rd readings after 10 minutes rest) on permitted background treatment >= 145 mmHg
- •4. Indication for diuretic treatment:
- •(a) Untreated + (age>55 AND/OR Black AND/OR renin<12mU/L)
- •OR (b) receiving ACEI/ARB
- •OR (c) receiving CCB
- •OR (d) receiving ACEI/ARB + CCB
- •5. At least one other component (i.e. additional to hypertension) of the metabolic syndrome (reduced HDL, raised triglycerides, glucose, waist circumference)*
- •* Definition of Metabolic Syndrome according to the International Diabetes Federation, 2006:
- •- Central obesity (waist circumference > 94cm male (>90 if Asian), > 80 female
- •- SBP = 130 or DBP = 85 mmHg
- •- Fasting glucose >5.6mmol/l
- •- Fasting Triglycerides > 1.7 mmol/l (or on rx)
- •- HDL < 1.03 mmol/l males, < 1.29 mmol/l females (or on rx)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusions :
- •The presence of any of the following will preclude patient inclusion
- •Diabetes (types 1 or 2)
- •Secondary hypertension
- •eGFR < 60 mls/min
- •Plasma K+ outside normal range on two successive measurements during screening
- •Home SBP at the end of placebo run-in >170 mmHg
- •Home DBP at the end of placebo run-in >115 mmHg
- •Requirement for treatment with >2 drugs (which can be a CCB and/or {ACEi OR ARB OR ß-blocker}) in order to reduced blood pressure to =170/115 mmHg
- •Requirement for diuretic therapy (other than for hypertension)
- •Requirement for both ß-blockade and ACE inhibitor (or ARB) therapy
- •Absolute contra-indications to any of the study drugs (listed on their data-sheet)
- •Current therapy for cancer
- •Anticipation of change in medical status during course of trial (e.g. surgical intervention requiring G.A., actual or planned pregnancy)
- •Inability to give informed consent
- •Not on stable doses of all concomitant medications for a minimum of 4 weeks prior to randomisation
- •Participation in a clinical study involving an investigational drug or device within 4 weeks of screening.
- •Any concomitant condition that, in the opinion of the investigator, may adversely affect the safety and/or efficacy of the study drug or severely limit the subject’s lifespan or ability to complete the study (eg, alcohol or drug abuse, disabling or terminal illness, mental disorders).
- •Treatment with any of the following prohibited medications:
- •a.Oral corticosteroids within 3 months of Screening. Treatment with corticosteroids is also prohibited during study participation.
- •b.Acetylsalicylic acid in excess of 325 mg per day.
- •c.Chronic stable or unstable use of non-steroidal anti-inflammatory drugs (NSAIDs) other than acetylsalicylic acid is prohibited. Chronic use is defined as >3 consecutive or nonconsecutive days of treatment per week. In addition, the intermittent use of NSAIDs is strongly discouraged throughout the duration of this study. If intermittent treatment is required, NSAIDs must not be used for more than a total of 2 days. For all subjects requiring analgesic or anti-pyretic agents, the use of paracetamol is recommended during study participation.
- •d.The use of short-acting oral nitrates (eg, sublingual nitroglycerin) is permitted; however, subjects should not take short-acting oral nitrates within 4 hours of Screening or any subsequent study visit.
- •e.The use of long-acting oral nitrates (eg, Isordil) is permitted; however, the dose must be stable for at least 2 weeks prior to Screening and Randomisation.
- •f.The use of sympathomimetic decongestants or ß-agonists is permitted; however, not within 1 week prior to Screening or Randomisation. In addition, use of these medications will be prohibited within 1 day prior to any clinic visit.
- •g.The use of theophylline is permitted; however, the dose must be stable for at least 4 weeks prior to Screening and throughout study participation.
- •h.The use of phosphodiesterase (PDE) type V inhibitors is permitted; however, subjects must refrain from taking these medications within 3 days of Screening or any subsequent study visit.
研究者
相似试验
已完成
2 期
A pilot trial of single versus dual diuretic therapy in the intensive care unitcritical careRenal and Urogenital - Other renal and urogenital disordersACTRN12623000624684Austin Hospital31
尚未招募
Unknown
Effect of combination diuretics in patients with acutely decompensated Heart Failure and Acute Kidney Injury: a randomized controlled clinical trialAcute Kidney InjuryRBR-2xjfkk8Faculdade de Medicina de Botucatu da Universidade Estadual Paulista
已完成
不适用
Comparison of diuretic actions of frusemide with Ayurvedic diureticsPatients requiring diuretic therapySLCTR/2007/010Faculty of Medicine, Colombo
已完成
不适用
Multicenter study of the effect of loop diuretics for liver function and kidney function for patients using tolvaptaPatient with cirrhotic ascites with concomitant loop diuretic who showed body weight loss of 1.5 kg or more at 1 week after tolvaptan administrationJPRN-UMIN000033223The third department of internal medicine, Nara Medical University100
招募中
4 期
Effect of one or two diuretics in patients with decompensated heart failure - a clinical trialHeart failureRBR-5qkn8hHospital de Clínicas de Porto Alegre